Open house drug discount agreements Safinamide, ATC N04BD03

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 553 days left·Open·Supplies·Framework

Structured notice only

Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Safinamid, ATC N04BD03

50/100

Opportunity Score

Needs reviewLow complexity

SuppliesFrameworkOpen

Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No guaranteed volume or minimum revenue. The agreement may be superseded by other discount contracts, leading to early...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Overview

Moderate opportunity

Key Facts

Framework procurement
Supplies contract
1 lot
Duration until Apr 2028
Non-exclusive discount agreements for the active substance Safinamide (ATC N04BD03) under § 130a Abs. 8 SGB V.
Contract duration: 24 months (01.05.2026 – 30.04.2028).

Show full summary

This is an open-house model (not a standard procurement procedure) by AOK Bayern for non-exclusive discount agreements on the active substance Safinamide (ATC N04BD03). Any interested pharmaceutical company that meets the eligibility criteria can conclude an identical, non-negotiable discount agreement. The contract runs from 01.05.2026 to 30.04.2028, and new contracts can be concluded at any time until 03.03.2028. The agreement automatically terminates if a nationwide or region-specific discount contract for the same substance comes into effect. No estimated value is provided, and no award criteria apply as all qualified companies are accepted.

Risks

No guaranteed volume or minimum revenue. The agreement may be superseded by other discount contracts, leading to early...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

Must be a pharmaceutical company.

Administrative

Submit a signed declaration of reliability.
Submit signed contract and annex ("Festlegung der vertragsgegenständlichen Arzneimittel").

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria (open-house model). All eligible companies are accepted.

Buyer

Name

AOK Bayern - Die Gesundheitskasse

Location

München, DEU

[email protected]

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open house drug discount agreements Safinamide, ATC N04BD03

Non-exclusive discount agreements for Safinamide (ATC N04BD03) with AOK Bayern. Open to all pharmaceutical companies meeting eligibility. Contract period: 01.05.2026 - 30.04.2028. Early termination possible with one month notice. Automatically void if other discount contracts for the same substance become effective.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Apr 2026 - Apr 2028

Procurement Details

Publication date: 15 Mar 2026
Languages: German

Reference metadata

Legal basis: 32014L0024

Reference IDs

Tender ID: 179421-2026

Documents (2)

Procurement document 1 Submission portal 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3